Robert Kavash Email and Phone Number
Robert Kavash work email
- Valid
- Valid
- Valid
Robert Kavash personal email
MEDICINAL, SYNTHETIC ORGANIC, and PRODUCT DEVELOPMENT CHEMISTRY:Medicinal chemist with expertise in synthesizing novel compounds and optimizing structure-activity relationships (SAR). Co-inventor of two marketed drugs [Intelence® (etravirine) for HIV and Viberzi® (eluxadoline) for IBS-D]. Creative thinking and strong synthetic skills as evidenced by 13 papers published in peer reviewed journals and 24 patents (22 issued in USA). A proven record of experience with all aspects of small molecule drug discovery:• Hit to lead • Lead optimization• De novo design • Scale upTherapeutic Area Experience:• Anti-infectives: antimalarial, antibacterial, antiviral, and antifungal• Heparin reversal agents (an application of peptidomimetic design)• Gastrointestinal disorders: irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD)Experience in Chemistry, Manufacturing, and Controls (CMC) product development, technology transfer, and consultation with contract research organizations (CROs) and contract manufacturing organizations (CMOs) to advance clinical projects for a small biotechnology company. Effective contributor in team environments; excellent collaborator.
Hager Biosciences, Llc
View-
Senior ScientistHager Biosciences, Llc Jan 2020 - PresentBethlehem, Pennsylvania, UsDrug Discovery through Medicinal and Synthetic Organic Chemistry.
-
Principal ScientistFox Chase Chemical Diversity Center Inc. Sep 2013 - Feb 2017Doylestown, Pennsylvania, UsDrug Discovery through Medicinal and Synthetic Organic Chemstry.Designed and synthesized novel molecular entities for a variety of therapeutic targets.• Jointly led a project that identified orally active small molecule non-peptidic mimics of host defense peptides (HDP’s) for the treatment of malaria.• Led a project with the goal of introducing drug-like properties into an existing series of inhibitors of both M2 wild type and M2-S31N mutant influenza A strains as a strategy towards a new therapeutic agent. Identified a compound with improved safety and pharmacokinetic properties. -
Research Scientist, Medicinal Chemistry And Product DevelopmentPolymedix, Inc. Feb 2007 - Apr 2013UsDesigned, synthesized, and performed CMC product development of novel fully synthetic small molecule non-peptidic mimics of host defense peptides (HDP’s) and other therapeutically relevant small polypeptides.• Analyzed antimalarial screening data to identify potent HDP leads with favorable safety profiles. Championed compound that was subsequently determined to possess in vivo efficacy via a novel mechanism of action. Jointly led the follow-on lead optimization program and designed and synthesized key analogs.• Consulted with process development CMO on GMP synthesis of PMX-30063 (brilacidin), an antibacterial compound that entered Phase II clinical trials.• Jointly led a backup program for heparin reversal agents that resulted in the discovery of compounds with an improved safety profile while broadening the activity profile to also reverse the effect of low molecular weight heparins. Designed and prepared key compounds.• Led and conducted exploratory process development research on heparin reversal compound PMX-60056 (delparantag), which entered Phase I clinical trials. Provided technology transfer to process development CRO and consulted on GMP synthesis. -
Senior Scientist, Drug Discovery, Enterology TeamJohnson & Johnson Pharmaceutical Research & Development 2000 - 2006New Brunswick, Nj, UsDesigned and synthesized novel molecular entities for the treatment of gastrointestinal disorders. • Co-designed and executed backup strategy for delta/mu-opioid receptor modulation project. Identified a compound with significant improvement in properties that met the requirements for selection as a backup candidate for early development.• Discovered a series of novel peripheral dual delta/mu-opioid receptor modulators as therapeutic agents for gastrointestinal disorders. As a co-inventor, solved conceptually and synthetically the problems of cardiovascular (CV) and P-450 inhibition liabilities, which enabled compound JNJ-27018966 to successfully transition into pre-clinical development. The compound, eluxadoline (MuDelta), was approved for marketing as Viberzi® in 2015 for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-D). • Led from conception through design and synthetic execution a small molecule tryptase inhibitor project as a strategy for IBD therapy. Identified lead compound for scale up and further evaluation. -
Senior Scientist, Medicinal ChemistryJanssen Research Foundation 1992 - 2000A Johnson and Johnson CompanyDevised and produced novel molecular entities for the treatment of a variety of therapeutic targets.• Co-inventor of TMC-125, a new generation non-nucleoside reverse transcriptase inhibitor currently marketed as Intelence® (etravirine) for the treatment of HIV. Designed and prepared key analogs. Received Janssen Research Foundation Pinnacle Award for this work.• Designed and synthesized key compounds for an anti-obesity project with a strategy of inhibition of the tripeptidyl-peptidase II (TPP II) enzyme. • Designed and synthesized key compounds for an anti–HIV project based on the mechanistic approach of non-nucleoside reverse transcriptase inhibitors. Increased potency from micromolar to nanomolar level against both wild type and mutant strains.
-
Post Doctoral FellowColorado State University 1990 - 1992Fort Collins, Co, UsProfessor Anthony Barrett Research Group -
Post Doctoral FellowNorthwestern University 1989 - 1990Evanston, Il, UsProfessor Anthony Barrett Research Group
Robert Kavash Skills
Robert Kavash Education Details
-
University Of MarylandOrganic Chemistry -
University Of VirginiaOrganic Chemistry
-
Roanoke CollegeChemistry
Frequently Asked Questions about Robert Kavash
What company does Robert Kavash work for?
Robert Kavash works for Hager Biosciences, Llc
What is Robert Kavash's role at the current company?
Robert Kavash's current role is Medicinal Chemistry / Synthetic Organic Chemistry / Product Development Chemistry.
What is Robert Kavash's email address?
Robert Kavash's email address is ro****@****msn.com
What schools did Robert Kavash attend?
Robert Kavash attended University Of Maryland, University Of Virginia, Roanoke College.
What skills is Robert Kavash known for?
Robert Kavash has skills like Medicinal Chemistry, Organic Chemistry, Chemistry, Drug Discovery, Organic Synthesis, Lc Ms, Nmr, Hplc, Chromatography, Purification, Pharmaceutical Industry, Biotechnology.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial